The human genome encodes over 20,000 genes, but it is estimated that there may be over one million distinct protein variants due to post-translational modifications (PTMs), allelic variation, and alternative splicing.
Proteomics can help scientists evaluate biomarkers and identify potential drug targets more comprehensively by analyzing changes in the proteome in diseased cells or tissues. It can also help evaluate the effectiveness of drugs in clinical studies by monitoring changes in protein expression levels in various diseased and therapeutic conditions.
Discovery Life Sciences offers customizable proteomic services, including proteome profiling, mechanism of action studies, biomarker discovery and integrated proteogenomics, enabling a comprehensive understanding of the proteome and accelerating drug and diagnostic development programs.
